Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay.

ABSTRACT: Visceral leishmaniasis is a neglected tropical disease with significant health impact. The current treatments are poor, and there is an urgent need to develop new drugs. Primary screening assays used for drug discovery campaigns have typically used free-living forms of the Leishmania parasite to allow for high-throughput screening. Such screens do not necessarily reflect the physiological situation, as the disease-causing stage of the parasite resides inside human host cells. Assessing the drug sensitivity of intracellular parasites on scale has recently become feasible with the advent of high-content screening methods. We describe here a 384-well microscopy-based intramacrophage Leishmania donovani assay and compare it to an axenic amastigote system. A panel of eight reference compounds w

SUBMITTER: De Rycker M 

PROVIDER: S-EPMC3697379 | biostudies-literature | 2013 Jul

REPOSITORIES: biostudies-literature